Introduction
Monoclonal antibodies (mAbs) are an important class of therapeutic molecules that are widely successful in treating numerous diseases and conditions, including cancer, inflammation, and immune disorders (Reichert, 2013 (Reichert, , 2014 . There are more than 30 antibodies that have been approved by US Food and Drug Administration, and many more are currently being developed (Reichert, 2010; Tabrizi and Roskos, 2007) .
The mAb consists of two functional parts, Fab (antigen binding fragment) and Fc (crystallizable fragment). Fab recognizes the target of the antibody, while the Fc domain is predominately responsible for non-target-associated interactions such as effector functions mediated by Fc receptors and C1q (Jiang et al., 2011) . Among several Fc receptors known to interact with IgG antibodies, neonatal Fc receptor (FcRn) plays a critical role in maintaining IgG homeostasis (Kacskovics et al., 2011) . After IgG binds to its target on the cell surface, it is pinocytosed to the endosome where FcRn binds to the CH2-CH3 junction of the mAb at pH 6 and recycles the mAb back into circulation at pH 7.4 (Burmeister et al., 1994; Rodewald and Kraehenbuhl, 1984; Roopenian and Akilesh, 2007; Ying et al., 2014) . The pH dependency of FcRn binding comes mostly from histidine residues His 310, His 435, and His 436 of IgG, which are protonated at pH 6 creating a strong interaction with the anionic pocket of FcRn; they are neutralized at pH 7.4 releasing IgG from FcRn (Medesan et al., 1997; Shields et al., 2001) . While FcRn-bound IgGs are protected and rescued from degradation, unbound IgG enters the lysosomal degradation pathway from the endosome resulting in a reduced amount of IgG in circulation (Ward, 2003; Ward et al., 2005) . Because FcRn binding affects the level of IgG in vivo, many researchers are currently investigating the relationship between FcRn affinity and the pharmacokinetic properties of IgG to better understand IgG homeostasis. Recent studies showed that IgG homeostasis is a complicated process that is affected by antibody characteristics and its therapeutic target as well as FcRn binding (Gurbaxani et al., 2006 (Gurbaxani et al., , 2013 Suzuki et al., 2010; Wang et al., 2011) . Still, it is clear that FcRn is critical for IgG homeostasis in vivo (Kacskovics et al., 2011; Kuo and Aveson, 2011; Zalevsky et al., 2010) . As such, a tool to study the in vitro binding of FcRn to IgG is needed, so that it can be used to engineer and screen FcRn-IgG interaction to improve the efficacy and dosing strategies for therapeutic mAbs. In addition, it can be used in characterization studies of IgG antibodies.
There are several types of FcRn binding assays, including cell-based fluorescent-activated cell scan (FACS) assays and those that are non-cell based such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) analysis. ELISA immobilizes FcRn (or IgG) on a plate and detects IgG (or FcRn) captured with secondary antibody conjugated with horseradish peroxidase or other enzymes (Ebersbach and Proetzel, 2012; Lu et al., 2011) . SPR is a widely used method to detect FcRn binding of IgG without any tag measuring both k on and k off (Bertolotti-Ciarlet et al., 2009; Magistrelli et al., 2012; Stapleton et al., 2011; Wang et al., 2011) . The cell-based FACS assay uses cells expressing FcRn on the surface and labeled IgG to measure the affinity (Hinton et al., 2005; Mathur et al., 2013) . While there are several assay formats available, there is still room for improvements for sensitivity, reproducibility/ consistency, as well as time requirements and cost.
Here, we describe the development of a homogenous AlphaScreen® -based FcRn binding assay as a general FcRn assay format, and we characterize the method. AlphaScreen technology provides sensitive detection of the low-affinity binding interaction between FcRn and IgG without needing any wash or secondary reagent, which could be a challenge with typical ELISA methods.
The AlphaScreen-based FcRn binding assay is a simple and quick method that can be used to measure FcRn binding of IgGs. FcRn-loaded donor beads and IgG1 mAb1-loaded acceptor beads are mixed together at once with various dilutions of sample IgG and simply incubated for 1 h before being read on a fluorescence reader. Up to four different samples can be tested in the same plate in 2 h by sharing donor and acceptor beads. The assay is accurate, precise and stability-indicating when critical residues for FcRn binding on the antibody are modified. The assay is also able to capture the impacts of antibody Fab region on FcRn binding and the assay format was found to be readily applied to other antibodies with minimal modifications.
Materials and methods
2.1. Materials mAb1, mAb2, mAb4, and mAb5 are IgG1 monoclonal antibodies, mAb3 is an IgG1 Fab antibody without Fc region, and mAb6 is an IgG4 monoclonal antibody. All antibodies are developed in Genentech, Inc. C-terminal AviTag FcRn was prepared as described previously (Schlothauer et al., 2013) , and used to prepare biotinylated hFcRn.
Preparation of biotinylated FcRn
BioA kit: Biotin-Protein Ligase (BirA) was purchased from Avidity, LLC (Aurora, CO; #BirA500). Biotinylation was performed following the manufacture's instruction.
Conjugation of acceptor beads with antibody
AlphaScreen unconjugated acceptor beads (1 mg; #6762003 PerkinElmer, Waltham, MA) were centrifuged and re-suspended in labeling solution (DPBS containing 2.2 mM NaBHCN and 0.1% polysorbate 20) before adding suitable amount of antibody to be conjugated. The mixture was then incubated for 16-20 h at 37°C with continuous shaking. The conjugation reaction was quenched by adding 600 mM of O-(carboxymethyl) hydroxylamine hemihydrochloride (CMO; #C13408-10G, Sigma-Aldrich) and further incubating the mixture at 37°C for 1 h with continuous shaking. At the end of the incubation, the antibody conjugated acceptor beads were centrifuged and re-suspended in PBS.
AlphaScreen-based FcRn binding assay
Briefly, first the test sample was diluted and loaded into each well of a 96-well 1/2 area plate (#6005560, PerkinElmer). Streptavidin-coated donor beads (#6760002, PerkinElmer) was diluted in assay diluent (50 μM in 100 mM sodium phosphate, 25 mM NaCl, pH 6.0, and 0.02% polysorbate 20) containing biotinylated FcRn, then added to each well of the 96-well 1/2 area plate and shaken for 1-2 min. The antibody conjugated acceptor beads were also diluted (50 μM) in assay diluent before being added to each well. After an incubation of about one hour, the fluorescent signal was obtained on the EnVision® 2104 Multilabel Plate Reader (PerkinElmer) with excitation at 680 nm and reading emission at 520-620 nm. The fluorescent signals of the reference material and the samples were plotted against concentrations using a four-parameter curve-fitting program (SoftMax Pro).
Relative binding activities were calculated by dividing the half maximal effective concentration (EC 50 ) of the reference material by the EC 50 of the samples.
Results and discussion

Development and characterization of the AlphaScreen-based FcRn binding assay
A homogenous AlphaScreen-based method was successfully developed for measuring antibody's binding to FcRn. This easy, simple, quick, robust method with high-throughput is useful for both IgG screening and biological characterization studies.
In this study using the AlphaScreen-based assay, biotinylated FcRn is loaded to donor beads, and IgG1 mAb1 is loaded to acceptor beads. Without the addition of any external IgG, FcRn binds to IgG1 mAb1, and the close proximity enables the transfer of 1 O 2 from donor beads excited at 680 nm to acceptor beads emitting a signal at 520-620 nm (Fig. 1) . Upon the addition of sample IgG, the competitive binding of the sample IgG to FcRn results in a different emitting signal for different sample IgG dilutions. From the competitive direct binding data of reference material and samples, the relative FcRn binding of sample IgGs was calculated. This assay can run up to four samples per plate in 2 h, which is time and cost effective compared to other FcRn binding methods such as cell-based fluorescent-activated cell scan and surface plasma resonance.
We further characterized the assay by conducting a study to evaluate the assay accuracy and precision. Briefly, mAb1 was diluted to nominal concentrations of 0.7, 1.0, and 1.3 mg/mL, corresponding to 70%, 100%, and 130% of the target concentration of 1.0 mg/mL, respectively. The protein concentrations of the dilutions were determined accurately by an ultraviolet spectrophotometric scan. The measured concentration of each sample was 0.698, 1.000, and 1.319 mg/mL, respectively. Each sample was subsequently diluted further into assay diluent and tested as described in Section 2.3. Each sample was assayed in five independent assays. To assess the accuracy of the assay, the measured activities were divided by the expected activities and expressed as percentage recoveries. The mean activities of three tested concentrations were 67%, 95%, and 125%, respectively, which represents percentage recoveries ranging from 95-96%. The inter-assay variability (relative standard deviation) was 6-11% (Table 1) .
In addition to method accuracy and precision, its specificity was also evaluated. When one IgG1 molecule with Fc region (mAb1) and another without Fc region (IgG1 Fab, mAb3) were tested side by side, the IgG1 molecule with Fc showed a dosedependent response curve, but the IgG1 molecule without Fc region (mAb3) did not show any response (Fig. 2) . This demonstrated that the method is specific for the IgG molecule with Fc region.
After the method accuracy, precision, and specificity were characterized, the ability of the assay to detect changes in Fc domain modification was evaluated using a panel of stressed mAb1 samples that had been subjected to various chemical and physical treatments, such as oxidation, elevated temperature, pH, and light. Each sample was diluted in the assay diluent and tested in three assays according to the method procedure described in Section 2.3. The activities of the stressed samples were normalized to the activity of the corresponding control. The results presented in Fig. 3A show that mAb1 samples subjected to thermal stress at 40°C for 31 days, basic pH, extended light exposure, and treatment with 3 mM 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH) had activities similar to their respective controls.
The mAb1 samples treated with 10 mM AAPH or acidic pH which had higher level of antibody HMWS demonstrated increased binding activity to FcRn. That is consistent with what was observed in other FcRn binding methods such as surface plasmon resonance (SPR) assays and the analytical FcRn affinity chromatography Mathur et al., 2013; Schlothauer et al., 2013) . The antibody aggregates or HMWS were found to exhibit a highly increased response signal and the slow off-rate in SPR, and longer retention time than monomeric IgG in the FcRn affinity column (Schlothauer et al., 2013) . This stronger interaction of HMWS with FcRn is probably due to avidity effects of the Fc parts. Furthermore, in the AlphaScreen-based method, strong correlation was observed between FcRn binding and the level of HMWS as shown in the insert of Fig. 3A . This evidence demonstrates that the AlphaScreen-based method can distinguish aggregation products from monomeric IgG. As with findings from other methods, the presence of HMWS should be considered when interpreting FcRn binding data.
Oxidation of Met252 and Met428 impairs binding of antibodies to FcRn and negatively affect PK (Liu et al., 2009; Schlothauer et al., 2013; Stracke et al., 2014) . Therefore, antibody samples under different oxidation treatment were analyzed in the AlphaScreen-based method. For mAb1 treated with 1% H 2 O 2 , reverse phase HPLC data revealed that approximately 99.6% of the heavy chains were oxidized. Size exclusion analysis of the untreated control and 1% H 2 O 2 stressed samples demonstrated comparable level of aggregates (0.2% vs 0.3%). When this stressed sample was tested in the Fig. 1 . AlphaScreen-based FcRn binding assay scheme. AlphaScreen-based method, the estimated FcRn binding was about 4% compared with the untreated control sample (Fig. 3A) demonstrating that AlphaScreen-based FcRn binding assay is able to detect the oxidation of the Fc Met residues impacting FcRn binding. For the control and samples treated with 3 mM, and 10 mM AAPH, the oxidation level of Met 252 varied from 7% to 30%, and the oxidation level of Met 428 varied from 4% to 21%. While the oxidation in these positions is known to reduce the binding of Fc to FcRn (Pan et al., 2009; Mathur et al., 2013; Stracke et al., 2014) , increased FcRn binding was observed for mAb1 AAPH-treated samples in the AlphaScreen-based FcRn binding assay due to the avidity effects by HMWS (Fig. 3A) . To see the effects of oxidation in the binding of mAb1 Fc to FcRn, the same samples were also tested using SPR analysis as an orthogonal testing method, which was intentionally designed in a way that only the 1:1 FcRn:IgG interaction is being examined in order to rule out the avidity effects. The data revealed that the mAb1 AAPH treated samples bind to FcRn at the levels comparable to that of the control. The K D values (FcRn:mAb = 1:1) at equilibrium for the control, 3 mM AAPH and 10 mM AAPH are 1.88 μM, 1.93 μM and 2.07 μM respectively. This indicates that oxidation of Met in this mAb1 AAPH treated samples has no impacts on 1:1 Fc to FcRn binding and the increased binding activity observed in the AlphaScreen-based FcRn binding assay is from the avidity effects of the aggregates.
As described by Stracke et al. (2014) , with the two Met residues present in each of the two heavy chains of an antibody, four oxidation sites exist in the IgG Fc, giving rise to a total of ten Fc oxidation variants containing zero to four Met oxidations per molecule. They found that antibody preparations with relatively high Fc Met oxidation levels (e.g. 40% oxMet252 and 25% oxMet428) do not show markedly impaired pharmacokinetic profiles (Stracke et al., 2014) .
We also applied this method to characterize minor antibody variants of mAb1. During manufacture of therapeutic antibodies, various forms of microheterogeneity, including size, charge, glycation, free thiol, and others, occur due to enzymatic processes or spontaneous degradation and modifications. During this study, several minor variants of mAb1 were isolated to characterize their binding to FcRn. Each variant was tested in three independent assays. As shown in Fig. 3B , the low molecular weight species (LMWS), charge (acidic and various acidic variants), free thiol, and glycation variants demonstrated similar FcRn binding activities as did the reference material (activities ranging from 91% to 110%). The basic variant, which contains a higher level of oxidation, was shown to have similar binding activities to the main peak. This is consistent with the findings of Khawli et al. (2010) , which demonstrated charge variants of IgGs do not affect the in vitro potency, FcRn binding affinity, or pharmacokinetic properties in rats.
General assay platform for applications in other molecules' characterization studies
YTE mutation of IgG1 molecule (mAb2)
Modulating FcRn-IgG interaction allows changing the therapeutic antibody's half-life and improving its efficacy; there are several strategies for engineering IgG mAbs for better FcRn binding and increased pharmacokinetic property (Igawa et al., 2013; Roopenian and Akilesh, 2007) . For example, various mutations at Thr250, Met252, Ser254, Thr307, Glu380, Met428, His433, and Asn434 improve the pH-dependent binding of IgG to FcRn (Dall'Acqua et al., 2006; Hinton et al., 2004 Hinton et al., , 2005 Kamei et al., 2005; Petkova et al., 2006; Shields et al., 2001; Vaccaro et al., 2005) . Also, YTE triple mutation (M252Y/S254T/T256E) in the CH2 domain of Fc is known to increase the binding of palivizumab to human FcRn by about 10-fold (Dall'Acqua et al., 2006) . In order to assess whether the AlphaScreen-based FcRn binding assay can detect the mutations in IgG Fc region, IgG1 mAb2 wild type and its YTE mutant sample were tested side by side. The results showed that YTE mutation did increase FcRn binding by about 6-fold (Fig. 4A ). It demonstrated that the AlphaScreen-based FcRn binding assay can detect the FcRn binding change caused by YTE mutation, and potentially could be used to screen IgG mAbs engineered for better FcRn binding.
Applications to other IgG isotypes
In order to evaluate whether the method can be used as a general platform for other molecules, two additional IgG1 molecules (mAb4, mAb5) with the same antibody framework and one IgG4 molecules (mAb6) were tested in this assay platform. The results demonstrated that the assay platform is suitable for testing both IgG1 and IgG4 molecules (Fig. 4B) . Using SPR analysis, it had been shown (Wang et al., 2011) that IgG1 mAbs having the same IgG Fc framework exhibit different FcRn binding activities suggesting that the different Fab of IgG mAbs may impact Fc-FcRn interaction as well. These results show that Fab potentially could induce different Fc conformation or indirectly alter the accessibility of Fc to FcRn for binding. In the AlphaScreen-based FcRn assay shown here, although both mAb4 and mAb5 have the same IgG Fc framework, different FcRn binding activities were observed, as indicated by the shift of binding curve. There was little difference in HMWS in mAb4 and mAb5 with 2.3% and 2% respectively. These results demonstrated that this AlphaScreen-based FcRn binding assay could capture potential conformational changes induced by the Fab to monitor their impact on FcRn binding.
Conclusion
A homogeneous AlphaScreen-based FcRn binding assay was successfully developed and evaluated as a general assay platform, which is simple, quick, and ready to apply to different types of IgG molecules with minimal modification. The assay was demonstrated to be precise and accurate, and it was able to detect changes in FcRn binding under different stress conditions. Furthermore, the assay shows specific interaction of FcRn to certain IgG isotypes (IgG1 and IgG4) but not to the Fab fragment. Different antibodies within the same IgG isotype were shown to have different binding affinities in the assay indicating the impact of the Fab portion of the antibody. For Fc mutations known to affect FcRn binding, we could detect the altered binding of FcRn to IgG mutants. Due its simplicity and high-throughput capability, the assay was successfully used to support various studies.
FcRn is a critical contributor to the half-life of therapeutic antibodies. An accurate, precise, specific, and user-friendly in vitro FcRn binding assay is a current need industry wide. It would facilitate the support of antibody engineering, process development, comparability studies, and biological characterization of pharmaceutical molecules. The method we present here provides a platform approach that can be readily applied to various antibodies.
